<DOC>
	<DOCNO>NCT00541489</DOCNO>
	<brief_summary>To study efficacy safety Naproxcinod v . Placebo Naproxen treatment sign symptom Osteoarthritis .</brief_summary>
	<brief_title>Efficacy Safety Study Naproxcinod Subjects With Osteoarthritis Hip</brief_title>
	<detailed_description>This 13 week randomize , double-blind , parallel group , multicenter study compare efficacy safety Naproxcinod , Placebo Naproxen .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Hip</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Naproxen-n-butyl nitrate</mesh_term>
	<criteria>Men woman ( 40 old ) diagnosis primary OA hip Must current chronic user NSAIDS acetaminophen Must discontinue analgesic therapy Screening Uncontrolled Hypertension Diabetes Hepatic renal impairment Current expect use anticoagulant Clinically relevant abnormal ECG A history alcohol drug abuse Diagnosis gastric duodenal ulceration and/or history significant gastroâ€‘duodenal bleeding , within last 6 month Current medical disease , include arthritic , could confound interfere evaluation efficacy Candidates imminent joint replacement Participation within 30 day prior screen another investigational study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>Osteoarthritis , Hip</keyword>
</DOC>